These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30030767)

  • 1. Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study.
    Stoppa G; D'Amore C; Conforti A; Traversa G; Venegoni M; Taglialatela M; Leone R;
    BioDrugs; 2018 Aug; 32(4):367-375. PubMed ID: 30030767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.
    Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S
    Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
    Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
    BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
    Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
    Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
    Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M
    J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
    Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
    Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study.
    Hustrini NM; Siregar P; Setiawati A; Nugroho P
    Acta Med Indones; 2019 Jul; 51(3):230-237. PubMed ID: 31699946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
    Shah HH; Fishbane S
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study.
    Kim Y; Park SK; Cho WY; Joo KW; Shin SK; Kim DJ; Kim YL; Son SH; Chung W; Lee KY; Park SK; Kim JK; Kim SW; Kang DH; Kim JK; Jeon JS; Lee KW; Lee CH; Oh DJ; An WS; Lee JS; Kang GW; Do JY; Lee JP; Jin K
    BioDrugs; 2020 Feb; 34(1):99-110. PubMed ID: 31749113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
    Covic A; Abraham I
    Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
    Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
    PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience.
    Dellanna F; Goldsmith D; Krendyukov A; Seidl A; Höbel N; Combe C
    Drug Des Devel Ther; 2018; 12():9-14. PubMed ID: 29296077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
    Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
    BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
    Aapro M; Krendyukov A; Schiestl M; Gascón P
    BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis.
    Yang J; Yu S; Yang Z; Yan Y; Chen Y; Zeng H; Ma F; Shi Y; Shi Y; Zhang Z; Sun F
    BioDrugs; 2019 Aug; 33(4):373-389. PubMed ID: 31161461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M; Vetter A; Thyroff-Friesinger U;
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
.
    London G; Mann J; Goldsmith D; Combe C; Dellanna F; Zaoui P; Hoebel N; Krendyukov A; MacDonald K; Abraham I
    Clin Nephrol; 2018 Jan; 89 (2018)(1):1-9. PubMed ID: 29168688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.